This study evaluated the long-term effectiveness and safety of 3-month versus 6-month modified FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) or CAPOX (capecitabine and oxaliplatin) treatment after surgery in patients with stage 3 colon cancer. The data showed that 3-month modified FOLFOX/CAPOX treatment was as effective and safe as the 6-month treatment over the long term in these patients.

This study evaluated the effectiveness and safety of adding PolyPepI1018 peptide vaccine to fluoropyrimidine/bevacizumab (Avastin) maintenance therapy in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC). The data showed that PolyPEPI1018 added to maintenance therapy was safe and associated with specific immune responses and antitumor activity in these patients.

This study evaluated the impact of immune checkpoint inhibitors (ICIs) on COVID-19 outcomes in patients with cancer. The data showed that the use of ICI treatment before COVID-19 infection does not affect the disease severity or survival outcomes. This study supports the continued use of ICIs in cancer patients during the pandemic.

This study compared the effectiveness and safety of immunotherapy versus standard treatment options in patients with metastatic colorectal cancer (mCRC). The data showed that immunotherapy tended to improve the survival outcomes in these patients.

This study compared the effectiveness of surgery with and without chemotherapy with uracil and tegafur (Uftoral; UFT) plus leucovorin (LV; folinic acid) in patients with stage II colon cancer. This study concluded that surgery with UFT/LV chemotherapy significantly improved survival outcomes in these patients.

This study evaluated the effectiveness of anatomical resection (AR) versus non-anatomical resection (NAR) in the surgery of lung metastases for patients with colorectal cancer (CRC). The data showed AR significantly improved cancer-specific survival outcomes compared to NAR in the surgery of lung metastases for patients with CRC.

This study evaluated the effectiveness and safety of bevacizumab (Avastin) plus TAS-102 (Lonsurf; trifluridine-tipiracil) versus TAS-102 alone for the treatment of patients with metastatic colorectal cancer (mCRC). The data showed that bevacizumab combined with TAS-102 was effective with manageable side effects in improving the outcomes of these patients.

This study investigated the effectiveness and safety of camrelizumab (SHR1210) in combination with XELOX (capecitabine and oxaliplatin) chemotherapy plus bevacizumab (Avastin) or regorafenib (Stivarga) as first-line therapy in patients with metastatic colorectal cancer (mCRC). The data showed that the combination was effective for these patients with manageable side effects.

This study evaluated the effectiveness and safety of chemotherapy given before surgery (neoadjuvant chemotherapy; NAC) followed by radiofrequency ablation (RFA) for the treatment of patients with colorectal cancer liver metastasis. The data showed that NAC plus RFA improved survival outcomes in these patients.

This study investigated the side effect profiles of different PD-1/PD-L1 inhibitor-based combination therapies. The data showed that PD-1/PD-L1 inhibitors in combination with chemotherapy were associated with a higher risk of treatment-related side effects than with targeted therapy or immunotherapy combinations.